Newcells Biotech is a private-equity backed biotech company focused on developing a range of cell based pre-clinical assays based on its core induced pluripotent stem cell (iPSC) technology. With the completion of a 2nd round £2m funding round in July 2018, the company has the resources to grow its existing kidney transport and nephrotoxicity platform and launch two more assays over the next two years. The company has a key differentiation in developing proprietary human cell 3-D assays for drug safety, DMPK and target validation/discovery.

Read the rest of entry »